60421-20-7

Usage

Uses

Used in Peptide Synthesis:
H-Aib-OBzl is used as a building block for the formation of larger peptide and protein structures due to its high stability and ability to withstand harsh reaction conditions. This makes it a crucial component in the development of new pharmaceuticals and therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, H-Aib-OBzl is used as a key component in the synthesis of bioactive peptides and proteins. Its stability and versatility contribute to the discovery and optimization of potential drug candidates.
Used in Biochemistry Research:
H-Aib-OBzl is utilized in the chemical modification of peptides and proteins for various research applications. Its protective group and benzyl ester functionality allow for precise manipulation and analysis of peptide and protein structures, aiding in the understanding of their biological functions and interactions.
Used in Chemical Modification of Peptides and Proteins:
H-Aib-OBzl is used as a modifying agent in the chemical alteration of peptides and proteins for industrial applications. Its protective properties and reactivity enable the development of modified peptides and proteins with tailored properties for specific uses in various industries.

Upstream product

• 55456-40-1 benzyl 2-aminoisobutyrate 
• 62-57-7 2-Aminoisobutyric acid 
• 100-51-6 benzyl alcohol 
• 100-44-7 benzyl chloride 
• 84758-57-6 tert-butoxycarbonylamino-2-methyl-propionic acid benzyl ester 

Downstream Products

• 134269-28-6 Boc-Gly-Aib-OBzl 
• 79118-35-7 Boc-L-Pro-Aib-OBzl 
• 79118-27-7 Boc-Val-Aib-OBzl 
• 79118-23-3 Boc-Leu-Aib-OBzl 
• 79118-31-3 Boc-Gln-Aib-OBzl 
• 55456-40-1 benzyl 2-aminoisobutyrate 
• 661481-25-0 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[(4-{2-[1-benzyloxycarbonyl-1-(methyl)ethylcarbamoyl]ethoxy}-2-methylphenyl)methyl]-5-isopropyl-1H-pyrazole 
• 661481-34-1 3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-4-[(4-{4-[1-benzyloxycarbonyl-1-(methyl)ethylcarbamoyl]but-1-ynyl}phenyl)methyl]-5-isopropyl-1H-pyrazole 
• 1029585-09-8 C₂₆H₃₉N₃O₆ 
• 1126529-10-9 Boc-ACPC-ACPC-Aib-OBn 
• 915087-33-1 enzalutamide 
• 1289942-66-0 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methyl propanoic acid 

Relevant academic research and scientific papers

ANTIVIRAL PRODRUGS OF TENOFOVIR

Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Antiviral phosphoramidates

The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,

PHOSPHORAMIDATE PRODRUGS FOR TREATMENT OF VIRAL INFECTION

The invention concerns 2'-methyl ribonucleotide phosphoramidates which are neutral prodrugs which are converted in vivo to 2'- methyl ribonucleotide triphosphates. These compounds are useful in the treatment of viral infection. Of particular interest are prodrugs of a methylsulfonylhydrazinyl purine 2'-methyl nucleotide triphosphate: 2'methyl- N6-alkyl-N6- (N-methylsulfonamide) adenosine triphosphate and its 2-amino derivative.

PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc. ; Z represents CO or SO2; R4 and R5 represent H, an optionally substituted C1-6 alkyl group etc.; and R3, R6 and R7 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF

The present invention provides fused heterocyclic derivatives represented by the general formula: wherein R1 represents H, halogen, OH, etc.; R2 represents H, halogen or an alkyl group; R3 and R4 represent H, OH, halogen, etc.; Q represents alkylene, etc.; ring A represents aryl or heteroaryl; and G represents or ???or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

CHEMICAL COMPOUNDS

Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an α-amino acid moiety. The α-amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid.